Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

clopidogrel

- PMLiVE

Uptake Strategies and Sanofi win capability development prize at PMEA

Judges praised their programme’s pragmatic design and huge scalability

- PMLiVE

Sanofi’s diabetes IMPACT programme wins at PMEA 2017

Takes home first place in Excellence in Demonstrating Economic and Societal Value

Sanofi reception

Sanofi licences Principia MS drug in $805m deal

Californian biotech is set to receive $765m plus in milestone payments if PRN2246 goes to market

Pharma’s digital patient engagement innovators identified

Novartis, Pfizer and Sanofi named best-in-class by Decision Resources Group

Sanofi reception

Dupixent dulls pain of diabetes slump at Sanofi

Biosimilar competition caused steep declines in its flagship product Lantus

Sanofi reception

Sanofi earmarks €170m for new French vaccines facility

Will expand its Val de Reuil production unit

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

NICE backs Sanofi’s Kevzara for routine NHS use

Recommends the RA treatment in combination with methotrexate

Sanofi reception

Sanofi, Regeneron claim EU approval for eczema drug Dupixent

Analysts suggest the product could be worth €5bn at peak

- PMLiVE

Sanofi looks to mobile data to power behavioural analysis

Teams up with Evidation Health for a new digital health partnership

- PMLiVE

Sanofi Genzyme brings The World Vs MS to Denmark

Firm's Communiqué Award winning campaign launches in another local market

Sanofi reception

Solid start for Dupixent as Sanofi raises 2017 outlook

Analysts predict dermatology medicine could become a €5bn product if approved in other indications

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links